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Background: Gaining understanding of the period before anti-
retroviral therapy (ART) is needed to improve treatment outcomes
and to reduce HIV transmission. This study describes the cascade of
enrollment in HIV care, pre-ART follow-up, and predictors of
mortality and lost to follow-up (LTFU) before ART initiation.
Methods: We conducted a cohort study among HIV-infected adult
patients not yet started on ART in 4 HIV Sub-Saharan African
programs. Patient follow-up began at enrollment and ended at the
earliest of death, transfer-out, ART initiation, last visit date, or
60 months postenrollment. Risk factors for death and LTFU were
investigated during the periods 0–6 and 6–60 months.
Results: A total of 55,789 patients (65.4% women) were included
as follows: 44.2% in clinical stage 3 or 4, with median CD4 of
261 cells per microliter [interquartile range (IQR): 125–447]. Patient
care started with a median of 3 days (IQR: 0–11) after HIV diagno-
sis, and 31,104 of 55,789 (55.8%) patients had CD4 counts per-
formed within 1 month of enrollment. Of 47,283 patients with
known ART eligibility status at enrollment, 36,969 (78.2%) patients
required ART and 27,798 of 36,969 (75.7%) patients initiated ther-
apy. Median follow-up was 2.5 months (IQR: 0.9–13.1). Mortality
and LTFU rates were 3.9 per 100 person-years [95% conﬁdence
interval (CI): 3.7 to 4.1] and 28.3 per 100 person-years (95% CI:
27.8 to 28.8), respectively. Regardless of period, increased mortality
and LTFU were associated with male, lower body mass index,
advanced clinical stage, and lower CD4 cell count.
Conclusions: Short delays between HIV testing and care enroll-
ment were observed in our HIV programs, but delays to determine
ART eligibility were long. Interventions to initiate ART earlier,
speciﬁcally targeted to men, are needed to improve patient retention
in Africa.
Key Words: adults, HIV, pre–antiretroviral therapy, mortality, lost
to follow-up, gender
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INTRODUCTION
The public health priority for the management of HIV-
infected patients is to provide access to combined antiretro-
viral therapy (ART), for those in need of treatment. This
explains why, until recently, most efforts have been invested
to scale-up access to ART in resource-limited settings, and
much of the research has focused on the evaluation of
treatment outcomes after the start of therapy.1,2 The success
of HIV programs was primarily judged on the basis of how
many patients start therapy instead of on the percentage of
patients eligible for and started on ART3 or on retention of
patients before the start of treatment. More recently, delays in
determination of patient eligibility have also been examined.
Nevertheless, evaluations of the effectiveness of HIV programs
should not be restricted to the study of retention in care of
patients receiving ART but should also consider their ability
to identify HIV-infected individuals, to timely determine eligi-
bility for ART, and to monitor and retain in care patients not
yet eligible.4,5 All these factors are important at individual level
to reduce HIV-related mortality and morbidity, and they may
contribute to decrease transmission of HIV infection.
Recently, Rosen and Fox6 reported that less than one-
third of patients testing positive for HIV in sub-Saharan Africa
receive uninterrupted HIV care before ART initiation. Reasons
for not starting ART despite patient eligibility include differ-
ences in eligibility criteria for therapy start, patient death or lost
to follow-up (LTFU) before treatment initiation, misinforma-
tion about the importance of pre-ART care, limited program
capacity, and insufﬁcient drugs and/or skilled health workers.
The relative importance of these reasons varies across countries
and HIV programs.
To improve the quality and effectiveness of HIV care, it
is necessary to monitor and evaluate patient follow-up before
and after the start of ART. The identiﬁcation of risk factors
associated with increased mortality and retention before the
start of therapy will help to improve patient long-term outcomes
of those subsequently starting ART. Most Medecins Sans
Frontieres (MSF)–supported HIV programs have electronic
monitoring data systems that include information on patients
receiving pre-ART care. In these programs, 20%–30% of the
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patients who are currently receiving HIV care have not yet
started ART (unpublished data, annual medical activities data,
Médecins Sans Frontières, December 2011). We know that
before the start of therapy, the dropout rate is high, especially
early after program enrollment. However, we know little about
the characteristics of these patients, about the factors associated
with LTFU, and about the dynamics of dropping out. As such,
we conducted a longitudinal study to evaluate the cascade
of engagement in HIV care, characteristics, outcomes, and
associated risk factors among patients not receiving ART in
4 HIV programs.
METHODS
Study Design and Study Population
We performed a longitudinal analysis of prospectively
collected electronic monitoring data from HIV-positive adult
patients ($15 years old) treated in 4 HIV programs supported
by MSF-France in sub-Saharan Africa (2 in Kenya: 1 in an
urban slum and the other in a rural district hospital; 1 highly
decentralized in a rural district of Malawi; and 1 in a rural
hospital district of Uganda). Patients were included if they
entered the HIV program between January 1, 2004, and
December 31, 2010, that is, at least 1 year before the admin-
istrative censoring of the database. Patient clinical and labo-
ratory data were collected prospectively using the FUCHIA
software (Follow-Up and Care of HIV Infection and AIDS,
Epicentre, Paris, France).
The pre-ART medical follow-up provided in programs
is performed in accordance with national guidelines, which
are based on the World Health Organization (WHO) recom-
mendations. HIV diagnosis is based on the existence of 2 HIV-
positive rapid antibody tests. Patients are seen by nurses, clinical
ofﬁcers, or medical staff every 3 or 6 months depending on their
level of immunosuppression. Clinical assessment encompasses
clinical staging and monitoring of nutritional status. CD4 cell
count testing is scheduled every 6 months and is used to
determine ART eligibility in patients with early stage of clinical
disease (WHO clinical stage 1 or 2). Viral load monitoring is
not routinely performed. Eligibility criteria for ART start
evolved over time following changes in WHO recommenda-
tion7–11 and was based on CD4 cell count levels and WHO
clinical staging as follows: CD4 cell count ,200 cells per
milliliter, clinical stage 4 irrespective of CD4 cell count; since
January 2007, clinical stage 3 irrespective of CD4 cell count;
and since March 2010, CD4 cell count ,350 cells per micro-
liter and/or WHO clinical stage 3 or 4. HIV care provision in
these sites started between April 2001 and September 2002. All
services related to HIV care, including laboratory testing, pro-
vision of combined ART, and management of opportunistic
infections and hospitalization, were free of charge.
Statistical Methods
Patient study follow-up started at the date of program
enrollment and ended at the earliest of death, transfer-out,
ART initiation, last clinical visit date, or 60 months
postenrollment. LTFU was deﬁned as having missed an
appointment for more than 6 months among patients who
had not initiated ART, been transferred outside the program,
or died during the study period.12
Patient characteristics were summarized using frequen-
cies and percentages for categorical variables and median and
interquartile range (IQR) for continuous variables. Access to
HIV care was assessed through calculation of the time
between HIV testing and enrollment in the program. We also
described the number of pre-ART visits per patient and the
time between successive clinic visits. To study the delay in
initial eligibility determination, we examined temporal changes
in the proportions of patients with a recorded CD4 cell count
measurement within 1 and 3 months of enrollment. To evaluate
the continuity of pre-ART care in the program, we reported the
frequency, duration, and timing of temporal interruptions in
follow-up (not attending a clinic visit for at least 60 days after
the appointment date). The delay in ART start was estimated
among ART eligible patients at enrollment (2010 deﬁnition:
CD4 cell count ,350 cells/mL and/or in WHO clinical stage
3 or 4) who initiated therapy.11
Kaplan–Meier estimates of mortality and LTFU were
calculated within 2 time periods, 0–6 and 6–60 months after
program entry. Risk factors for mortality and LTFU were
evaluated using a parametric survival model with Weibull
distribution for the 0-month to 6-month period, when mortality
and LTFU rates were higher; and a Cox proportional hazards
models for the 6-month to 60-month period. Factors considered
for adjustment were as follows: sex, age (continuous variable),
mode of entry in the program (in- or outpatient services, vol-
untary counseling and testing or prevention of mother-to-child
transmission of HIV infection, medical referral, other, and
missing), WHO clinical stage (1, 2, 3, 4, and missing), CD4
cell count (,50, 50–199, 200–349, 350–499,$500, and miss-
ing cells/mL), body mass index (BMI: ,18.5, $18.5, and
missing kg/m2), previous history of ART use, and recorded
diagnosis of tuberculosis. In addition, we ﬁtted separate Cox
proportional hazards models to obtain estimates of associations
with the baseline ART eligibility status that did not include
initial clinical stage and CD4 cell count to avoid colinearity.
Final multivariable models were ﬁtted using a backward step-
wise approach. Statistical signiﬁcance was assessed with the
likelihood ratio test at 5% level. All estimates were adjusted for
year of program inclusion and site. In addition, complete case
analyses to assess the impact of missing data on our estimates
were performed by excluding patients who had incomplete
covariate data (CD4 counts, clinical stage, and BMI) from
the population analyzed. We also performed a competing
risk analysis to obtain risk factor estimates of mortality
adjusted for LTFU.13
Analyses were performed using Stata 12.1 software
(Stata Corporation, College Station, TX).
Ethical Considerations
All MSF-supported projects are implemented in collab-
oration with the Ministry of Health and within the frame of
signed Memorandums of Understandings. Electronic monitor-
ing data are collected in agreement with the Ministry of Health
to monitor and evaluate the HIV programs. The study was
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approved by the Comité de Protection des Personnes de Saint
Germain en Laye, Paris, France.
RESULTS
A total of 55,789 adult patients were included in the
analyses, 54.3% of them were treated in Malawi, 26.1% in
Uganda, and 19.6% in Kenya. The number of patient
inclusions remained stable over the study period.
Patients were enrolled in the programs in median 3
days (IQR: 0–11) after being tested positive for HIV. The
percentages of individuals with a recorded CD4 cell count
within 1 and 3 months of inclusion were 55.8% and 70.1%,
respectively. These percentages increased over time from
9.3% and 27.3% in 2004 to 77.8% and 86.7% in 2010,
respectively (P , 0.001).
At program enrollment, patient median age was 33 years
(IQR: 27.5–40.0) and 65.4% of individuals were women
(Table 1). The median BMI was 19.6 kg/m2 (IQR: 17.7–21.7),
10.1% of patients had a recorded diagnosis of tuberculosis,
and 44.2% were in stage 3 or 4 (n = 22,779). Sixty-three
percent of patients had CD4 ,350 cells per microliter (n =
24,837). Only 307 individuals had history of ART (0.6%)
and/or prevention of mother-to-child transmission of HIV
infection use (2.9%) before program entry.
Men were more likely to present at an advanced stage
of disease than women; 52.3% of men were in clinical stage 3
or 4 compared with 39.8% of women (P , 0.001); and
median CD4 cell count was lower in men (203 vs 0.291
cells/mL, P , 0.001).
Study Follow-Up and Interruption of HIV Care
Overall, median duration of pre-ART follow-up per
patient was 2.5 months (IQR: 0.9–13.1). Median duration of
follow-up for individuals who received HIV care for more
than 6 months (n = 20,686) was 19.1 months (IQR: 11.1–33.5).
During the study follow-up, a total of 5348 patients
(9.6%) interrupted HIV care temporarily at least once for a
median duration of 109 days (IQR: 77–214). Eighty-ﬁve per-
cent of interruptions happened during the 6-month to 60-month
period (median duration of 126 days, IQR: 84–254), and the
proportion of patients with temporal care discontinuations
remained stable over time.
ART Eligibility and Therapy Start
Of the 47,283 patients with known ART eligibility
status at enrollment, 36,969 (78.2%) required ART. Patients
who were eligible at enrollment had a median follow-up of
1.5 months (IQR: 0.9–4.6), those who were not eligible had a
median follow-up of 18.4 months (IQR: 8.5–32.2), and
patients with unknown eligibility status had a median follow-
up of 6.2 months (IQR: 0.7–21.1). Among eligible patients,
27,998 (75.7%) started ART during the study follow-up
(Fig. 1). Of those not initially eligible, 5103 became eligible
during the study follow-up and were started on therapy. Before
ART initiation, patients had a median number of 1 CD4 cell
count measurement (IQR: 0–2), and 4 clinic visits (IQR: 2–8)
with intervals between visits of 1.02 months (IQR: 0.60–2.76).
The overall median delay in ART start was 2.1 months (IQR:
0.9–8.2) for the 34,719 patients who initiated treatment and
was 1.5 months (IQR: 0.9–3.9) for the 27,998 patients who
were eligible and started ART. This delay was positively asso-
ciated with the initial CD4 count levels (P, 0.001), 1.2 months
for patients with CD4 ,50 cells per microliter, 1.3 months for
50–199 cells per microliter, 3 months for 200–349 cells per
microliter, 15.9 months for 350–499 cells per microliter, and
23.5 months for .500 cells per microliter. Among patients
eligible for and initiated on ART at enrollment, 9610 (34.3%)
received treatment within 1 month of program entry, median
delay before ART start being 1.5 months (IQR: 0.9–3.9).
Mortality
Overall, 1843 of 55,789 (3.3%) patients died before
receiving ART, a median of 1.6 months (IQR: 0.7–4.4), after
program entry. About 1399 (75.9%) of the deaths were
among patients eligible for therapy at program inclusion.
TABLE 1. Patient Characteristics at Enrollment in the HIV
Programs of Malawi, Kenya, and Uganda, 2004–2010
(N = 55,789)
Characteristics
Women, n (%) 36,508 (65.4)
Median age (IQR), (yrs) 33.0 (27.5–40.0)
BMI (kg/m2)
Median (IQR) 19.6 (17.7–21.7)
,18.5 18,583 (35.0)
$18.5 35,229 (65.0)
Missing 1907
Clinical stage, n (%)
1 17,834 (34.6)
2 10,950 (21.2)
3 15,373 (29.8)
4 7406 (14.4)
Missing 4226
CD4 cell count (cells/mL)
Median (IQR) 261 (125–447)
,50 3934 (10.1)
50–199 11,423 (29.2)
200–349 9480 (24.2)
350–499 6407 (16.4)
$500 7843 (20.1)
Missing 16,702
History of ART use, n (%) 307 (0.6)
Diagnosis of tuberculosis, n (%) 5651 (10.1)
Mode of program entry, n (%)
In- or outpatient services 30,358 (65.0)
VCT or PMTCT 9826 (21.1)
Medical referral 4170 (8.9)
Other 2329 (5.0)
Missing 9106
PMTCT, prevention of mother-to-child transmission of HIV infection; VCT,
voluntary counseling and testing.
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The overall rate of mortality was 3.9 per 100 person-years.
Cumulative estimates were 1.3% [95% conﬁdence interval
(CI): 1.2% to 1.5%] at 1 month (rate: 41.5 per 100 person-
years), 3.8% (95% CI: 3.6% to 4.0%) at 6 months (1–6
months rate: 9.8 per 100 person-years), 4.6% (95% CI:
4.3%–4.8%) at 12 months (6–12 months rate: 1.7 per 100
person-years), and 5.6% (95% CI: 5.4%–5.9%) at 24 months
(12–24 month rate: 1.2 per 100 person-years). Mortality was
signiﬁcantly higher in patients eligible for ART initiation than
in those not eligible (log-rank test P , 0.001; Fig. 2A). Rates
were 8 per 100 person-years and 0.9 per 100 person-years,
respectively, and 2.6 per 100 person-years for patients with
unknown eligibility status.
Results of the multivariate analysis are presented in
Table 2. Six-month mortality was higher in patients with initial
advanced clinical disease [adjusted hazard ratio (aHR) = 5.96,
95% CI: 4.90 to 7.23 for stage 4 compared with stage 1].
Mortality was lower in women than in men (aHR = 0.65,
95% CI: 0.59 to 0.72) in patients with higher CD4 cell count
(aHR = 0.11, 95% CI: 0.08 to 0.15 for .500 compared with
,50 cells/mL) and in those with BMI $18.5 kg/m2 (aHR =
0.39, 95% CI: 0.34 to 0.44 compared with ,18.5 kg/m2).
The same risk factors for mortality were identiﬁed during the
6–60 month period, with the highest hazard ratio observed for
patients in clinical stage 4 (aHR = 3.0, 95% CI: 1.95 to 4.62).
Long-term pre-ART mortality also increased with age (10 years
unit aHR = 1.19, 95% CI: 1.08 to 1.30) and was higher in
patients diagnosed with tuberculosis (aHR = 1.65, 95% CI:
1.13 to 2.40).
FIGURE 1. Flow chart of patients
included in the study, Malawi, Kenya,
and Uganda, 2004–2010.
FIGURE 2. Kaplan–Meier estimates of mortality (A) and LTFU
(B) of patients receiving pre-ART HIV care stratified by eligi-
bility status at program entry in Malawi, Kenya, and Uganda,
2004–2010.
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Compared with patients not eligible for ART at pro-
gram entry, those eligible had aHR = 6.29 (95% CI: 4.85 to
8.16) during the ﬁrst 6 months of follow-up and 2.24 (95%
CI: 1.73 to 2.90) during the 6–60 month period. Patients with
unknown eligibility status had aHR = 4.42 (95% CI: 3.31 to
5.91) and 1.16 (0.83–1.61), respectively (Table 2).
Analyses restricted to patients with complete data showed
consistent results. Results obtained from the competing-risk
regression were similar to those obtained with the Cox model
(where LTFU were considered as censored), although the size
of the estimates was generally smaller (Table 2).
Lost to Follow-Up
A total of 12,765of 55,789 (22.9%) patients were LTFU
before receiving ART in median 1.5 months (IQR: 0.03–7.72)
TABLE 2. Associations Between Individual-Level Factors and Mortality During the 0–6 and 6–60 Months Pre-ART Follow-Up
Periods in Malawi, Kenya, and Uganda, 2004–2010
Characteristics
at Inclusion
0–6 Months 6–60 Months
Crude HR (95% CI)
Adjusted HR
(95% CI)
Adjusted SHR
(95% CI)
Crude HR (95%
CI)
Adjusted HR
(95% CI)
Adjusted SHR
(95% CI)
Sex
Male 1 1 1 1 1 1
Female 0.45 (0.40 to 0.49) 0.65 (0.59 to 0.72) 0.70 (0.63 to 0.78) 0.43 (0.35 to 0.53) 0.59 (0.48 to 0.74) 0.63 (0.50 to 0.79)
Age in years
(per 10 unit
increase)
1.11 (1.06 to 1.17) — — 1.29 (1.18 to 1.41) 1.19 (1.08 to 1.30) 1.22 (1.10 to 1.35)
BMI (kg/m²)
,18.5 1 1 1 1 1 1
$18.5 0.21 (0.18 to 0.23) 0.39 (0.34 to 0.44) 0.42 (0.37 to 0.48) 0.43 (0.35 to 0.53) 0.61 (0.49 to 0.77) 0.62 (0.48 to 0.80)
Missing 3.48 (2.97 to 4.08) 3.10 (2.63 to 3.65) 2.04 (1.71 to 2.43) 2.60 (1.40 to 4.82) 2.28 (1.21 to 4.29) 1.30 (0.61 to 2.79)
Clinical stage
1 1 1 1 1 1 1
2 1.68 (1.36 to 2.07) 1.31 (1.06 to 1.62) 1.34 (1.08 to 1.65) 1.61 (1.21 to 2.12) 1.48 (1.11 to 1.97) 1.41 (1.05 to 1.90)
3 4.19 (3.54 to 4.97) 2.61 (2.17 to 3.14) 2.33 (1.93 to 2.81) 2.51 (1.93 to 3.27) 1.95 (1.44 to 2.66) 1.78 (1.29 to 2.44)
4 14.07 (11.87 to 16.68) 5.96 (4.90 to 7.23) 4.73 (3.86 to 5.79) 5.39 (3.70 to 7.85) 3.00 (1.95 to 4.62) 2.15 (1.30 to 3.54)
Missing 2.01 (1.53 to 2.64) 1.73 (1.30 to 2.29) 1.66 (1.25 to 2.20) 1.13 (0.74 to 1.73) 1.16 (0.75 to 1.80) 1.12 (0.72 to 1.76)
CD4 cell count
(cells/mL)
,50 1 1 1 1 1 1
50–199 0.30 (0.25 to 0.37) 0.44 (0.36 to 0.53) 0.45 (0.37 to 0.55) 0.45 (0.19 to 1.06) 0.67 (0.28 to 1.62) 1.20 (0.41 to 3.52)
200–349 0.10 (0.08 to 0.12) 0.18 (0.14 to 0.23) 0.24 (0.18 to 0.30) 0.10 (0.05 to 0.20) 0.20 (0.09 to 0.44) 0.35 (0.13 to 0.92)
350–499 0.07 (0.05 to 0.09) 0.15 (0.12 to 0.21) 0.22 (0.16 to 0.29) 0.07 (0.03 to 0.14) 0.15 (0.07 to 0.32) 0.27 (0.11 to 0.72)
$500 0.04 (0.03 to 0.06) 0.11 (0.08 to 0.15) 0.15 (0.11 to 0.21) 0.05 (0.03 to 0.11) 0.13 (0.06 to 0.29) 0.25 (0.09 to 0.65)
Missing 0.63 (0.54 to 0.73) 1.45 (1.23 to 1.71) 1.17 (0.99 to 1.39) 0.10 (0.05 to 0.20) 0.22 (0.10 to 0.47) 0.28 (0.11 to 0.73)
Diagnosis of
tuberculosis
No 1 — — 1 1 1
Yes 3.38 (3.00 to 3.82) — — 4.36 (3.21 to 5.92) 1.65 (1.13 to 2.40) 1.46 (0.96 to 2.22)
Mode of program
entry
VCT or
PMTCT
1 — — 1 1 1
In- or outpatient
services
1.26 (1.10 to 1.46) — — 1.26 (0.96 to 1.64) 1.43 (0.98 to 2.08) 1.51 (1.02 to 2.21)
Medical referral 1.50 (1.21 to 1.85) — — 0.73 (0.44 to 1.23) 0.67 (0.39 to 1.17) 0.67 (0.38 to 1.19)
Other 1.51 (1.18 to 1.94) — — 0.87 (0.45 to 1.69) 1.07 (0.51 to 2.24) 1.04 (0.48 to 2.23)
Missing 0.54 (0.43 to 0.68) — — 0.95 (0.64 to 1.40) 1.38 (0.78 to 2.44) 1.31 (0.79 to 2.16)
Eligibility to ART
at enrollment*
No 1 1 1 1 1 1
Yes 9.26 (7.18 to 11.95) 6.29 (4.85 to 8.16) 5.16 (4.00 to 6.66) 2.64 (2.09 to 3.34) 2.24 (1.73 to 2.90) 2.02 (1.56 to 2.63)
Unknown 5.26 (3.96 to 6.98) 4.42 (3.31 to 5.91) 3.53 (2.64 to 4.71) 1.28 (0.95 to 1.73) 1.16 (0.83 to 1.61) 1.09 (0.76 to 1.55)
* CD4 cell count and clinical stage were not included in this model for estimations of HR and SHR.
PMTCT, prevention of mother-to-child transmission of HIV infection; HR, hazard ratio; SHR, subhazard rate ratio; VCT, voluntary counseling and testing.
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after program entry, 6157 (48.2%) of them were eligible
for ART at inclusion. The overall LTFU rate was 28.3 per
100 person-years. Kaplan–Meier cumulative estimates were
11.1% (95% CI: 10.9% to 11.4%) at 1 month (rate: 161.5/100
person-years), 21.7% (95% CI: 21.3% to 22.2%) at 6 months
(1–6 month rate 64.9/100 person-years), 28.2% (95% CI:
27.7% to 28.7%) at 12 months (6–12 month rate: 17.5 per
100 person-years), and 36.2% (95% CI: 35.6% to 36.8%) at
24 months (12–24 month rate: 15.9 per 100 person-years).
Higher estimates were found in patients eligible for ART at
program entry (Fig. 2B), with rates of 38.3 per 100 person-
years, compared with rates 16.5 per 100 person-years in
patients not eligible and 34.2 per 100 person-years in individ-
uals with unknown eligibility status.
As observed for mortality, being LTFU during the ﬁrst
6 months of HIV care was associated with severe HIV disease
at program inclusion (Table 3). Higher ratios were seen in
patients in clinical stage 3 (aHR = 1.27, 95% CI: 1.20 to 1.36)
or 4 (aHR = 1.69, 95% CI: 1.56 to 1.83). Lower ratios were
found in patients with BMI$18 kg/m2 (aHR = 0.85, 95% CI:
0.80 to 0.89), CD4 cell count .50 cell s per microliter, in
women (aHR = 0.71, 95% CI: 0.68 to 0.74), and in individuals
of older age (aHR = 0.84, 95% CI: 0.82 to 0.86, per 10 unit
increase). The same associations were identiﬁed during the
6-month to 60-month period.
The aHR for ART eligible patients were 1.40 (95% CI:
1.31 to 1.49) in the 0–6 months and 1.12 (95% CI: 1.03 to
1.22) in the 6–60 months period, and 2.86 (2.67 to 3.07) and
1.16 (1.05 to 1.27), respectively, for patients with unknown
eligibility status at program entry (Table 3). Analyses restricted
to patients with complete data showed consistent results.
DISCUSSION
We report the outcomes of HIV-positive patients regis-
tered in 4 HIV African programs before the start of ART.
Despite short delays in enrollment in HIV care after HIV
testing, most patients presented with advanced stage of HIV
disease, and 75.7% of those eligible for treatment were started
on ART. Before the start of therapy, 23% of patients dropped
out and 3% died. Increased mortality and LTFU were observed
in patients presenting with advanced HIV disease and in men.
Compared with patients not eligible for ART, those eligible
had a 6-fold increased risk of death during the ﬁrst 6 months of
care and a 2-fold increase in the following four-and-half years.
Some studies in resource-limited countries have described
pretreatment mortality and LTFU rates in HIV-infected
adults,5,14,15 but very few of them were conducted in rural
settings. In Uganda and Gambia, mortality rates among pa-
tients eligible for ART (WHO stage 3 or 4 or CD4 cell count
,200/mL) were 27 per 100 person-years16 and 21.9 per 100
person-years among eligible patients infected with HIV-1 and/
or HIV-2,17 respectively. Those rates were higher than the 8 per
100 person-years reported in our programs. Differences are
likely to be partly explained by differences in tracing of LTFU
patients to ascertain the vital status of patients. In our programs,
mortality is underestimated, given the large proportion of
LTFU and the fact that patients who do not receive ART
and fail to attend their clinic appointments are not routinely
traced. This is also suggested by the similarity in patient base-
line clinical characteristics between LTFU patients and those
who died; and it is supported by ﬁndings of a previous eval-
uation conducted in Malawi showing that 49% of patients
LTFU before receiving ART between July 2004 and
September 2007 had died.18 Ingle et al found even worse
outcomes with overall pre-ART mortality rates of 53.2 per
100 person-years among eligible patients (CD4 ,200 cells/
mL) enrolled in a large HIV program in South Africa. Dis-
parities in population characteristics originated from various
settings, utilization of restrictive eligibility criteria (CD4 ,
200 cells/mL) coupled to a good ascertainment of vital status
through efﬁcient linkage to death registries probably explain
their worse ﬁndings. The pre-ART mortality rate found in
a rural Ethiopian cohort was 13.1 per 100 person-years,19
which is higher than the 3.9 per 100 person-years rate observed
in our programs. Again death status was ascertained among
LTFU patients, and patients were enrolled in care at a more
advanced stage of disease (62% were stage 3 or 4 compared
with 44% in our report). In rural Kenya, the pre-ART LTFU
rate in patients not eligible at 6 months of follow-up was 11.1
per 100 person years,20 which is lower than the rate of 21.5 per
100 person-years observed in our cohorts during the same
observation period. Applying to our data, the method devel-
oped by Brinkhof et al21 to correct mortality estimates at 1
year of ART taking into account the rate of follow-up, the
mortality estimate at 1 year increased from 4.6% (95% CI:
4.3% to 4.8%) to 12.3% (95% CI: 7.4% to 17.6%).
Two of 3 patients were eligible for ART at program
inclusion and, as expected, treatment eligibility was associated
with increased early and late mortality during pre-ART follow-
up. Patients started ART in median 1-and-a-half month after
program enrollment. Although delays in treatment initiation
were shorter for severely immunosuppressed patients, waiting
times were too long and could be further reduced by decreasing
the length of precounseling sessions and concomitantly
reinforcing counseling during the ﬁrst months of ART. For
instance, in Cape Town, South Africa, delays of 34 days have
been achieved,4 and good outcomes have been reported among
patients treated with ART.22,23 The scaling up of point of care
CD4 testing tools planned in our programs in the coming
months should also contribute to reduce the number of patient
visits necessary for initial clinical evaluation and determination
of ART eligibility.24,25 This is expected to lead to decrease
delays in ART initiation, especially among paucisymptomatic
patients. Further reducing pre-ART mortality will require
strengthening of the whole cascade of HIV care, starting from
testing at an earlier stage of the disease, through implementa-
tion of new strategies to promote HIV testing at community
level and delivery of CD4 count results on the same day of the
initial clinical evaluation; to achieving effective enrollment and
retention in pre-ART HIV care to start therapy as soon as the
patients become eligible. Barriers to care access need to be
adequately understood and addressed (eg, knowledge of the
asymptomatic phase of disease, stigma, or direct and indirect
costs related to health care)20,26,27 and adapted strategies adop-
ted. For instance, logistical challenges are frequently faced by
patients (eg, travel distance and transportation fees) and efforts
to minimize these need to be undertaken.
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Outcomes and characteristics of patients who are not
eligible for ART have been poorly described in the litera-
ture.5,28,29 In the programs studied, the high rate of LTFU
observed among this group of patients highlights the difﬁculties
faced by health workers to retain patients not eligible and fre-
quently asymptomatic patients in care. Differences in rates of
LTFU according to eligibility status were smaller than for mor-
tality, especially after the ﬁrst 6 months of care. It is likely that
many of the patients who do not require therapy and who
discontinue HIV care will return to the clinics when symptoms
of late disease develop at a later stage. Because of the high
workload in our programs, priority was given to the manage-
ment of more severe cases and fewer efforts were invested to
encourage retention of asymptomatic patients. Improvement of
outcomes can only be achieved if sufﬁcient resources are avail-
able and an enhanced standard package of pre-ART care is
provided (eg, adapted counseling or social support).
In this study, women were less likely to die or be LTFU
regardless of the severity of HIV disease at clinic presentation.
Similar sex-related disparities in both access to care and
clinical outcomes have been described in the literature and
are unlikely to be explained by the physiological lower CD4
count levels in men.30 Men are frequently diagnosed at a later
stage of HIV disease (ie, more advanced clinical stage and
lower CD4 cell counts) and consequently present late and more
severely immunosuppressed.31 Smaller proportions of men are
TABLE 3. Associations Between Individual-Level Factors and LTFU During the 0–6 and 6–60 Months Pre-ART Follow-Up Periods in
Malawi, Kenya, and Uganda, 2004–2010
Characteristics at Inclusion
0–6 Months 6–60 Months
Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI)
Sex
Male 1 1 1 1
Female 0.70 (0.67 to 0.73) 0.71 (0.68 to 0.74) 0.62 (0.58 to 0.67) 0.62 (0.58 to 0.67)
Age in years (per 10 unit increase) 0.86 (0.84 to 0.88) 0.84 (0.82 to 0.86) 0.81 (0.78 to 0.84) 0.79 (0.76 to 0.82)
BMI (kg/m2)
,18.5 1 1 1 1
$18.5 0.69 (0.66 to 0.72) 0.85 (0.80 to 0.89) 0.79 (0.73 to 0.85) 0.93 (0.92 to 1.21)
Missing 3.60 (3.33 to 3.90) 2.99 (2.76 to 3.25) 3.12 (2.49 to 3.91) 2.89 (2.30 to 3.63)
Clinical stage
1 1 1 1 1
2 0.84 (0.79 to 0.89) 0.85 (0.79 to 0.90) 1.03 (0.94 to 1.12) 1.04 (0.95 to 1.13)
3 1.25 (1.19 to 1.32) 1.27 (1.20 to 1.36) 1.19 (1.09 to 1.29) 1.09 (0.99 to 1.21)
4 2.23 (2.09 to 2.37) 1.69 (1.56 to 1.83) 1.73 (1.47 to 2.03) 1.56 (1.30 to 1.87)
Missing 0.95 (0.87 to 1.04) 1.10 (1.00 to 1.21) 0.73 (0.64 to 0.83) 1.05 (0.92 to 1.21)
CD4 cell count (cells/mL)
,50 1 1 1 1
50–199 0.60 (0.52 to 0.68) 0.66 (0.58 to 0.76) 0.54 (0.30 to 0.97) 0.80 (0.44 to 1.44)
200–349 0.54 (0.47 to 0.61) 0.60 (0.53 to 0.69) 0.30 (0.18 to 0.50) 0.59 (0.35 to 0.98)
350–499 0.67 (0.59 to 0.76) 0.71 (0.63 to 0.81) 0.28 (0.17 to 0.46) 0.52 (0.32 to 0.87)
$500 0.79 (0.70 to 0.89) 0.82 (0.72 to 0.93) 0.31 (0.19 to 0.51) 0.56 (0.34 to 0.93)
Missing 2.77 (2.48 to 3.09) 3.93 (3.51 to 4.40) 0.39 (0.24 to 0.65) 0.73 (0.44 to 1.21)
Diagnosis of tuberculosis
No 1 1 1 1
Yes 1.22 (1.14 to 1.30) 0.75 (0.70 to 0.81) 1.91 (1.66 to 2.20) 1.25 (1.07 to 1.47)
History of ART use
No 1 — 1 1
Yes 0.79 (0.53 to 1.18) 1.51 (0.84 to 2.73) 1.74 (0.96 to 3.16)
Mode of program entry
VCT or PMTCT 1 1 1 1
In or outpatient services 0.81 (0.77 to 0.86) 1.07 (1.00 to 1.15) 0.91 (0.84 to 0.99) 1.10 (0.99 to 1.22)
Medical referral 0.71 (0.64 to 0.78) 1.06 (0.96 to 1.18) 0.74 (0.64 to 0.86) 1.00 (0.85 to 1.17)
Other 1.14 (1.03 to 1.25) 1.21 (1.08 to 1.35) 1.57 (1.35 to 1.82) 1.30 (1.10 to 1.54)
Missing 0.83 (0.77 to 0.89) 1.66 (1.49 to 1.85) 0.78 (0.69 to 0.88) 1.31 (1.11 to 1.55)
Eligibility to ART at enrollment*
No 1 1 1 1
Yes 1.50 (1.41 to 1.59) 1.40 (1.31 to 1.49) 1.19 (1.10 to 1.28) 1.12 (1.03 to 1.22)
Unknown 2.78 (2.61 to 2.96) 2.86 (2.67 to 3.07) 10.5 (0.97 to 1.14) 1.16 (1.05 to 1.27)
* CD4 cell count and clinical stage were not included in this model for estimations of HR.
HR, hazard ratio; PMTCT, prevention of mother-to child-transmission of HIV infection; VCT, voluntary counseling and testing.
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followed up in HIV programs5,32 and start ART, partly because
they interrupt care more frequently than women.16 Once on
ART, poorer treatment outcomes16,31,33239 have also been
reported. Men might suffer from speciﬁc forms of stigma or
feel that they were less vulnerable to HIV infection than
women. Better understanding of both, the barriers in access-
ing and the factors facilitating long-term retention in HIV care
among men, is important to design appropriate innovative
interventions speciﬁcally designed for this high-risk group.
Strategies of decentralization of HIV testing and care services
to the work place might be effective in some contexts.
Because the study was based on the analysis of electronic
monitoring data, estimates were not adjusted for some potential
confounding factors such as socioeconomic and marital status
or household distance to HIV clinic.14 Although missing data
on CD4 cell count or clinical stage may bias study estimates,
results of the complete case analysis were consistent with those
obtained when variables including separate categories for miss-
ing data were used. Second, deaths were not ascertained and
the reasons for being LTFU were unknown. Therefore, we
cannot exclude outcome misclassiﬁcation for a certain propor-
tion of LTFU patients who might have died. However, the
competing-risk regression, where LTFU were considered as
a competing event for death, showed consistent results and
provided evidence of robustness of our ﬁndings.
In conclusion, this analysis identiﬁed several areas of
improvement including the need to increase access to HIV
program at an earlier stage of disease and to improve pre-
ART care to maximize program retention and timely start of
ART. Comprehensive evaluations of HIV programs should
include the study of patients not started on therapy, a descrip-
tion of delays in treatment start as patients become eligible for
treatment, and quantiﬁcation of care discontinuation for both
patients eligible and not eligible for ART. In the context of
scaling up of HIV testing, the study of temporal trends in
these indicators is important to inform program managers
about the successes or insufﬁciencies of the operational
strategies adopted. Particular attention should be paid to the
effective linkage to care and long-term retention of patients
not yet eligible for treatment, especially among men.
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